(600223)"LUSHANG FREDA PHARMACEUTICAL CO., LTD."Announcement on Key Operating Data for Q3 2026
Filed with SSE · Stock code 600223 · · 2 pages · Chinese
Summary by 6ix AI
The report details the production, sales, and revenue of the company's main products during this period. It also covers price changes for major products and raw materials, highlighting significant fluctuations. Additionally, the filing states that there are no other significant matters affecting the company's operations.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/600223lushang-freda-pharmaceutical-co-ltdannouncement-on-key-operating-data-for-q3-2026
Lushang Freda Pharmaceutical Co., Ltd. on 6ix
Story so far
Earlier from Lushang Freda Pharmaceutical
- (600223)"LUSHANG FREDA PHARMACEUTICAL CO., LTD."Announcement on Appointment of Senior Executives
- (600223)"LUSHANG FREDA PHARMACEUTICAL CO., LTD."Announcement on Departure of Director and Senior Executive
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Completion of Transfer Registration of Certain Company Shares by the Controlling Shareholder through Agreement
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
Follow Lushang Freda Pharmaceutical into a list and get an email when it puts out news.
Follow Lushang Freda Pharmaceutical